CDSCO vs US FDA vs EU MDR: Medical Device Regulatory Comparison

Navigating medical device regulations across major markets is one of the most important challenges for manufacturers pursuing global market access. India, the United States and the European Union each operate distinct regulatory frameworks designed to ensure the safety, quality and performance of medical devices.

Understanding the differences between India's Central Drugs Standard Control Organisation (CDSCO) under the Medical Devices Rules, 2017 (MDR 2017), the US Food and Drug Administration (FDA), and Regulation (EU) 2017/745 on medical devices (EU MDR) is essential for developing an effective regulatory strategy.

This comparison highlights the key elements of each framework, including regulatory authorities, classification systems, market-entry pathways, quality management requirements and post-market obligations.

Regulatory Authorities and Legal Frameworks

India – CDSCO and Medical Devices Rules, 2017

In India, medical devices are regulated by the Central Drugs Standard Control Organisation (CDSCO) under the Ministry of Health and Family Welfare. The Medical Devices Rules, 2017 provide the principal regulatory framework for medical devices and in-vitro diagnostic medical devices.

The regulatory system involves both the Central Licensing Authority (CLA) and State Licensing Authorities (SLAs), depending on the risk classification and regulatory activity.

Medical devices are classified according to the risk-based principles specified in the First Schedule of MDR 2017. CDSCO also publishes classification lists for medical devices and IVDs.

For imported medical devices, applications for an import licence are submitted to the Central Licensing Authority through the CDSCO online system, SUGAM. The foreign manufacturer must comply with the applicable requirements for import and appoint an authorised representative/agent in India as required under the applicable regulatory provisions.

United States – US Food and Drug Administration

In the United States, medical devices are regulated by the US Food and Drug Administration (FDA), primarily through the Center for Devices and Radiological Health (CDRH).

The FDA regulates medical devices under the Federal Food, Drug, and Cosmetic Act and applicable provisions of Title 21 of the Code of Federal Regulations (21 CFR).

Unlike the EU system, the US regulatory framework is centrally administered by the FDA. Depending on device classification and regulatory pathway, manufacturers may require FDA clearance, authorization or approval before commercial distribution.

European Union – EU MDR

Medical devices in the European Union are regulated under Regulation (EU) 2017/745, commonly known as the EU Medical Device Regulation (EU MDR).

The EU system differs from the centralized FDA model. Regulatory oversight involves national Competent Authorities, designated Notified Bodies and other EU regulatory mechanisms.

Manufacturers demonstrate conformity with applicable EU MDR requirements and, where required, undergo conformity assessment by a Notified Body before affixing the CE marking.

Manufacturers established outside the European Union are generally required to appoint an EU Authorized Representative.

Risk-Based Classification Systems

All three jurisdictions use risk-based classification principles. However, the number of classes, classification rules and regulatory consequences differ.

India – CDSCO Classification

Under MDR 2017, medical devices other than IVD medical devices are classified according to Part I of the First Schedule.

The four risk classes are:

• Class A – Low risk
• Class B – Low-moderate risk
• Class C – Moderate-high risk
• Class D – High risk

Examples may include:

• Class A: Certain low-risk examination and general medical devices
• Class B: Devices such as certain needles, syringes and monitoring devices
• Class C: Certain ventilators, diagnostic imaging equipment and implants
• Class D: Certain high-risk implantable and life-supporting devices

The final classification should always be determined based on the device's intended purpose, applicable classification rules and the latest CDSCO classification information.

For manufacturing activities, the regulatory authority generally depends on device class and the applicable provisions of MDR 2017. Class A and Class B devices fall within the State Licensing Authority framework, while Class C and Class D devices are regulated by the Central Licensing Authority. Import licences are granted by the Central Licensing Authority.

United States – FDA Classification

The FDA classifies medical devices into three categories:

• Class I – Low risk
• Class II – Moderate risk
• Class III – High risk

Class I devices are subject to general controls, and many—but not all—are exempt from premarket notification requirements.

Class II devices generally require special controls in addition to general controls. Many Class II devices reach the market through the 510(k) Premarket Notification pathway, where substantial equivalence to an appropriate legally marketed predicate device is demonstrated.

Certain novel devices for which no suitable predicate exists may be considered through the De Novo classification process.

Class III devices generally require Premarket Approval (PMA) unless another legally applicable pathway applies.

European Union – EU MDR Classification

The EU MDR classifies medical devices into:

• Class I – Low risk
• Class IIa – Medium risk
• Class IIb – Medium-high risk
• Class III – High risk

Class I devices may also include specific subclasses such as:

• Class Is – Sterile devices
• Class Im – Devices with a measuring function
• Class Ir – Reusable surgical instruments

Classification is determined using the rules contained in Annex VIII of the EU MDR. These rules consider factors such as intended purpose, invasiveness, duration of contact, active functionality and the anatomical site involved.

Because classification directly influences conformity assessment, clinical evidence and regulatory oversight, manufacturers should establish the correct classification early in product development.

Premarket Pathways and Evidence Requirements

India – CDSCO Market Access

For medical devices regulated under MDR 2017, manufacturers and importers must follow the applicable licensing or registration requirements based on the nature of the device and regulatory activity.

Applications are submitted through the CDSCO regulatory system, including the SUGAM portal where applicable.

Depending on the device and application type, regulatory submissions may require documentation such as:

• Device description and intended use
• Device Master File or equivalent technical documentation
• Plant Master File
• Quality Management System documentation
• ISO 13485 certification or applicable evidence of compliance
• Risk management documentation
• Clinical evaluation or clinical investigation data, where applicable
• Labelling and Instructions for Use
• Essential Principles of Safety and Performance compliance documentation

The level of regulatory scrutiny generally increases with device risk.

Manufacturers should avoid relying on fixed approval timelines because actual timelines may vary depending on device classification, completeness of documentation, regulatory queries, inspection requirements and the need for additional clinical evidence.

United States – FDA Premarket Pathways

The principal FDA market-entry pathways include:

510(k) Premarket Notification

Many Class II devices are regulated through the 510(k) process. The manufacturer generally demonstrates that the device is substantially equivalent to a legally marketed predicate device.

De Novo Classification

The De Novo pathway may be available for certain novel low- or moderate-risk devices for which no suitable predicate device exists.

Premarket Approval (PMA)

Many Class III devices require PMA. This pathway generally requires valid scientific evidence demonstrating reasonable assurance of safety and effectiveness.

The evidence required may include non-clinical testing, clinical data, manufacturing information and other scientific documentation depending on the device.

European Union – EU MDR Conformity Assessment

Under the EU MDR, manufacturers must demonstrate compliance with the applicable General Safety and Performance Requirements and prepare technical documentation.

For most devices, conformity assessment involves a Notified Body.

Certain Class I devices may be self-certified by the manufacturer, provided they are not:

• Sterile devices
• Devices with a measuring function
• Reusable surgical instruments
• Devices subject to other requirements that trigger Notified Body involvement

Clinical evaluation is a fundamental requirement under the EU MDR. Manufacturers must establish and maintain sufficient clinical evidence to support device safety and performance throughout the product lifecycle.

Following successful conformity assessment, the manufacturer may issue the EU Declaration of Conformity and affix the CE marking, subject to fulfilment of applicable regulatory requirements.

Quality Management Systems

A quality management system is a critical component of medical device regulatory compliance across all three jurisdictions.

India – MDR 2017

Manufacturers are required to comply with the applicable quality management system requirements under the Medical Devices Rules, 2017. Schedule V establishes requirements broadly aligned with internationally recognized medical device quality management principles.

ISO 13485 certification is commonly used as evidence supporting compliance with medical device quality management requirements, subject to the applicable CDSCO regulatory provisions.

United States – FDA QMSR

The FDA's quality system requirements have undergone an important regulatory change.

Effective February 2, 2026, the FDA's revised 21 CFR Part 820, known as the Quality Management System Regulation (QMSR), incorporates ISO 13485:2016 by reference, together with additional FDA-specific requirements.

Therefore, it is no longer accurate to describe the former Quality System Regulation (QSR) as the current FDA quality system framework.

Manufacturers entering the US market should assess compliance with the current QMSR requirements and applicable FDA-specific provisions.

European Union – EU MDR

The EU MDR requires manufacturers to establish and maintain a quality management system appropriate to the device and the risk associated with it.

ISO 13485 certification is widely used by manufacturers as a practical framework for demonstrating quality management system compliance. However, ISO 13485 certification alone does not automatically demonstrate complete compliance with all EU MDR requirements.

Post-Market Surveillance and Regulatory Obligations

Post-market responsibilities are significant in all three jurisdictions.

India – CDSCO

Manufacturers and other responsible entities must comply with applicable post-market surveillance and vigilance requirements under the Indian regulatory framework.

Depending on the device and applicable provisions, obligations may include:

• Reporting of adverse events
• Field safety corrective actions
• Post-market surveillance
• Complaint handling
• Regulatory reporting of significant changes

Manufacturers should maintain systems capable of monitoring device performance throughout its lifecycle.

United States – FDA

FDA post-market obligations may include:

• Medical Device Reporting (MDR)
• Corrections and removals reporting, where applicable
• Post-market surveillance requirements
• Post-approval studies for certain devices
• Complaint handling and quality system controls
• Unique Device Identification requirements, where applicable

The exact obligations depend on the device type and applicable FDA requirements.

European Union – EU MDR

The EU MDR places substantial emphasis on lifecycle management and post-market surveillance.

Key requirements may include:

• Post-Market Surveillance (PMS)
• Post-Market Clinical Follow-up (PMCF), where applicable
• Vigilance reporting
• Periodic Safety Update Reports (PSURs) for applicable device classes
• Trend reporting
• Field Safety Corrective Actions
• Summary of Safety and Clinical Performance (SSCP) for applicable implantable and Class III devices

Manufacturers must continuously collect and evaluate post-market data to confirm the ongoing safety and performance of their devices.

Key Differences at a Glance

Practical Implications for Global Manufacturers

The differences between CDSCO, FDA and EU MDR requirements create both regulatory challenges and opportunities for global manufacturers.

A strong international regulatory strategy should begin with a robust core technical documentation package covering areas such as:

• Device description and intended purpose
• Risk management
• Verification and validation
• Biological safety
• Clinical evaluation
• Usability and human factors
• Labelling
• Quality management
• Post-market surveillance planning

Jurisdiction-specific requirements can then be addressed for each target market.

These may include:

• CDSCO licensing and India-specific documentation
• FDA premarket submission requirements
• EU MDR technical documentation and conformity assessment
• Appointment of regional representatives
• Jurisdiction-specific UDI requirements
• Local vigilance and post-market reporting obligations

One of the most common mistakes in global regulatory planning is assuming that approval or certification in one jurisdiction automatically guarantees acceptance in another. While existing data can often be leveraged, each regulatory authority applies its own legal requirements and evidence standards.

Early regulatory gap analysis can help manufacturers identify differences before investing heavily in product development or market-entry activities.

Conclusion

CDSCO, the US FDA and the EU MDR share a common objective: protecting patients and users by ensuring that medical devices placed on the market meet appropriate standards of safety, quality and performance.

However, their regulatory structures, classification systems, market-entry pathways and post-market obligations differ significantly.

For manufacturers planning international expansion, regulatory strategy should begin early. Correct classification, a clearly defined intended purpose, robust clinical evidence and a globally adaptable quality management system can reduce duplication and prevent avoidable regulatory delays.

At MDR Consultants, we support medical device and IVD companies in understanding and navigating regulatory requirements across India and international markets. From classification and regulatory gap assessment to technical documentation, licensing support and post-market compliance, a well-planned regulatory roadmap can help manufacturers approach market access with greater clarity and confidence.

Last Updated : 05 Sep 2026